Overview Dividends

(AZN) AstraZeneca - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US0463531089

Oncology, Cardiovascular, Respiratory, Rare-Disease, Vaccines

AZN EPS (Earnings per Share)

EPS Growth (3Y CAGR): 21.92%
EPS Trend (3Y Correlation): 48.9%

AZN Revenue

Revenue Growth (3Y CAGR): 11.70%
Revenue Trend (3Y Correlation): 96.0%

Risk via 10d forecast
Volatility	24.5%
Value at Risk 5%th	36.5%
Relative Tail Risk	-4.03%

Reward TTM
Sharpe Ratio	1.26
Alpha	31.45

Character TTM
Hurst Exponent	0.581
Beta	0.399
Beta Downside	0.547

Drawdowns 3y
Max DD	27.87%
Mean DD	9.92%
Median DD	9.79%

Description: AZN AstraZeneca September 24, 2025

AstraZeneca PLC (NASDAQ: AZN) is a globally diversified biopharmaceutical firm that discovers, develops, manufactures and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare-disease segments. Its product slate includes high-growth oncology agents such as Tagrisso, Imfinzi and Lynparza, as well as leading cardiovascular drugs like Farxiga and Brilinta, and respiratory inhalers such as Symbicort and Breztri.

The company reaches physicians through a mix of direct sales forces and third-party distributors in the United Kingdom, United States, Europe and Asia. Recent strategic moves include a multimodal AI-driven oncology model with Tempus, a quantum-accelerated chemistry partnership with IonQ, and a joint discovery program with CSPC Pharmaceutical targeting oral small-molecule candidates. These collaborations are intended to shorten R&D cycles and expand AZN’s pipeline breadth.

Financially, AstraZeneca reported FY 2023 revenue of $44.4 billion, with oncology contributing roughly 38 % of sales and delivering a 12 % YoY growth rate. R&D expenditure remained steady at $7.1 billion (≈16 % of revenue), reflecting a commitment to pipeline renewal. The stock trades at a forward-PE of about 15×, below the sector median of ~18×, and offers a dividend yield near 2.5 %.

Key sector drivers that could materially affect AZN’s outlook include the aging global population (projected to increase the over-65 demographic by 30 % by 2035), sustained US healthcare spending growth (~5 % CAGR), and accelerating adoption of AI-enabled drug discovery, which may improve hit-to-clinic conversion rates across the industry.

For a deeper quantitative assessment of AZN’s valuation metrics and forward cash-flow projections, the ValueRay platform offers a transparent, data-driven model worth exploring.

AZN Stock Overview

Market Cap in USD	262,244m
Sub-Industry	Pharmaceuticals
IPO / Inception	1993-05-12
Return 12m vs S&P 500	22.0%
Analyst Rating	4.42 of 5

AZN Dividends

Dividend Yield	1.72%
Yield on Cost 5y	3.05%
Yield CAGR 5y	1.48%
Payout Consistency	96.4%
Payout Ratio	35.9%

AZN Growth Ratios

CAGR 3y	13.54%
CAGR/Max DD Calmar Ratio	0.49
CAGR/Mean DD Pain Ratio	1.36
Current Volume	4090.5k
Average Volume	4514.8k

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (9.40b TTM) > 0 and > 6% of Revenue (6% = 3.49b TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 3.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -7.08% (prev -3.46%; Δ -3.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 15.14b > Net Income 9.40b (YES >=105%, WARN >=100%)

Net Debt (24.52b) to EBITDA (18.12b) ratio: 1.35 <= 3.0 (WARN <= 3.5)

Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (3.12b) change vs 12m ago 0.06% (target <= -2.0% for YES)

Gross Margin 82.28% (prev 80.88%; Δ 1.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 52.99% (prev 48.80%; Δ 4.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.42 (EBITDA TTM 18.12b / Interest Expense TTM 1.57b) >= 6 (WARN >= 3)

Altman Z'' 0.97

(A) -0.04 = (Total Current Assets 29.94b - Total Current Liabilities 34.05b) / Total Assets 114.46b

(B) 0.07 = Retained Earnings (Balance) 8.21b / Total Assets 114.46b

(D) 0.16 = Book Value of Equity 10.64b / Total Liabilities 68.48b

Total Rating: 0.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.10

1. Piotroski 8.0pt = 3.0

2. FCF Yield 3.89% = 1.94

3. FCF Margin 19.18% = 4.79

4. Debt/Equity 0.71 = 2.25

5. Debt/Ebitda 1.35 = 1.22

6. ROIC - WACC (= 7.54)% = 9.43

7. RoE 21.80% = 1.82

8. Rev. Trend 96.02% = 7.20

9. EPS Trend 48.91% = 2.45

What is the price of AZN shares?

As of November 15, 2025, the stock is trading at USD 89.10 with a total of 4,090,547 shares traded.
Over the past week, the price has changed by +5.34%, over one month by +4.68%, over three months by +13.55% and over the past year by +39.86%.

Is AstraZeneca a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, AstraZeneca (NASDAQ:AZN) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.10 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZN is around 95.52 USD . This means that AZN is currently overvalued and has a potential downside of 7.21%.

Is AZN a buy, sell or hold?

AstraZeneca has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy AZN.

Strong Buy: 6
Buy: 5
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the AZN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	93.3	4.7%
Analysts Target Price	93.3	4.7%
ValueRay Target Price	104.8	17.7%

AZN Fundamental Data Overview November 11, 2025

Market Cap USD = 262.24b (262.24b USD * 1.0 USD.USD)
P/E Trailing = 28.0997
P/E Forward = 16.3132
P/S = 4.5116
P/B = 5.7997
P/EG = 0.9658
Beta = 0.169
Revenue TTM = 58.13b USD
EBIT TTM = 13.18b USD
EBITDA TTM = 18.12b USD
Long Term Debt = 26.51b USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.58b USD (from shortTermDebt, last quarter)
Debt = 32.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.52b USD (from netDebt column, last quarter)
Enterprise Value = 286.72b USD (262.24b + Debt 32.66b - CCE 8.18b)
Interest Coverage Ratio = 8.42 (Ebit TTM 13.18b / Interest Expense TTM 1.57b)
FCF Yield = 3.89% (FCF TTM 11.15b / Enterprise Value 286.72b)
FCF Margin = 19.18% (FCF TTM 11.15b / Revenue TTM 58.13b)
Net Margin = 16.17% (Net Income TTM 9.40b / Revenue TTM 58.13b)
Gross Margin = 82.28% ((Revenue TTM 58.13b - Cost of Revenue TTM 10.30b) / Revenue TTM)
Gross Margin QoQ = 81.16% (prev 82.89%)
Tobins Q-Ratio = 2.51 (Enterprise Value 286.72b / Total Assets 114.46b)
Interest Expense / Debt = 1.07% (Interest Expense 349.0m / Debt 32.66b)
Taxrate = 21.86% (709.0m / 3.24b)
NOPAT = 10.30b (EBIT 13.18b * (1 - 21.86%))
Current Ratio = 0.88 (Total Current Assets 29.94b / Total Current Liabilities 34.05b)
Debt / Equity = 0.71 (Debt 32.66b / totalStockholderEquity, last quarter 45.89b)
Debt / EBITDA = 1.35 (Net Debt 24.52b / EBITDA 18.12b)
Debt / FCF = 2.20 (Net Debt 24.52b / FCF TTM 11.15b)
Total Stockholder Equity = 43.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.21% (Net Income 9.40b / Total Assets 114.46b)
RoE = 21.80% (Net Income TTM 9.40b / Total Stockholder Equity 43.11b)
RoCE = 18.93% (EBIT 13.18b / Capital Employed (Equity 43.11b + L.T.Debt 26.51b))
RoIC = 14.30% (NOPAT 10.30b / Invested Capital 72.05b)
WACC = 6.75% (E(262.24b)/V(294.90b) * Re(7.49%) + D(32.66b)/V(294.90b) * Rd(1.07%) * (1-Tc(0.22)))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 80.01% ; FCFE base≈9.39b ; Y1≈10.65b ; Y5≈14.53b
Fair Price DCF = 81.13 (DCF Value 251.54b / Shares Outstanding 3.10b; 5y FCF grow 15.61% → 3.0% )
EPS Correlation: 48.91 | EPS CAGR: 21.92% | SUE: 0.44 | # QB: 0
Revenue Correlation: 96.02 | Revenue CAGR: 11.70% | SUE: 1.11 | # QB: 2

Additional Sources for AZN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle